Introduction
As we enter what has been termed the post-genomic era (Vukmirovic and Tilghman, 2000) , even greater emphasis will be placed on the functional relationships between genes. Nowhere is this emphasis more relevant than in the large group of human malignancies which harbor aberrant transcription factors (Rabbitts, 1994) . While aberrant transcription factors are presumed to function through the deregulation of tumorigenic pathways, the identi®cation of these pathways has come slowly (Vogt et al., 1999) .
The pediatric solid tumors Ewing's Sarcoma and peripheral Primitive Neuroectodermal Tumor (PNET), the Ewing Family Tumors (EFT), are an excellent example of the present problems in functional genomics. Virtually all EFT's are associated with oncogenic chimeric proteins which fuse amino-terminal EWS with the DNA binding moiety of an ETS transcription factor (FLI-1 in 90% of cases) (Delattre et al., 1992; . These chimeras function as transcription factors which are biochemically distinct from either parent gene (May et al., 1993b) . Attempts to identify the downstream targets of these chimeras on the basis of dierential gene regulation have produced targets with little apparent association with tumor biology (Arvand et al., 1998; Braun et al., 1995; Lawlor et al., 1998; Thompson et al., 1996; Welford et al., 1998) . Clearly, if we are to understand the important role that aberrant transcription factors play in EFT and other human malignancies, further systematic identi®cation of downstream pathways is necessary.
One current approach is to utilize microarray technology to produce and analyse the expression pro®les of large numbers of tumors until patterns emerge (Golub et al., 1999) . Results to date suggest that substantial biologic variability will be an obstacle to this approach (Perou et al., 2000) . As an alternative approach, we have used highly ecient retroviral systems to biologically screen for transforming genes which are directly or indirectly transcriptionally deregulated as a consequence of the EWS/FLI aberrant transcription factor. With this approach, we have identi®ed the recently described PDGF-C (Li et al., 2000) as a target of EWS/ETS transcriptional deregulation. PDGF-C is upregulated by several variant EWS/ETS transcription factors. Like EWS/ FLI, PDGF-C demonstrates substantial in vitro transforming and in vivo tumorigenic activity in a model system. PDGF-C is also expressed in EFT cell lines and in primary tumors. Finally, PDGF-C expression is dependent upon EWS/FLI activity in EFT cell lines. These results suggest that PDGF-C may be a signi®cant mediator of EWS/FLI driven transformation and oncogenesis. Additionally, our isolation of PDGF-C further demonstrates the utility of phenotypic expression cloning in unraveling complex biologic processes.
Results

An expression cloning strategy detects a novel EWS/FLI target gene
In order to isolate transforming genes which are dierentially regulated by EWS/FLI, we employed a retroviral-based expression system (Whitehead et al., 1995) . The phenotype employed was EWS/FLI induced transformation of NIH3T3 cells (May et al., 1993a) . cDNA was isolated from two polyclonal NIH3T3 populations ± retrovirally transduced with either EWS/FLI or empty retroviral vector. These lines were passaged and selected in parallel. In order to avoid repeated isolation of EWS/FLI, we employed a comparably active (data not shown) EWS/FLI construct with a NotI site at the chimeric junction. After cDNA synthesis, NotI digestion was used to inactivate EWS/FLI cDNA's. Adapted cDNA was ligated into a retroviral vector and packaged into retroviral cDNA stocks. NIH3T3 cells were transduced with retroviral cDNA stocks derived from each cell population. Each cDNA transduced population was then plated in soft agar, using conditions in which EWS/FLI readily induces formation of transformed foci. After incubation, foci were found only in the cells transduced with EWS/FLI cDNA. Inserts from each focus were recovered by PCR. To screen out false positives, recovered inserts from each primary focus were subcloned into a secondary retroviral vector and the resulting retrovirus was used to transduce fresh NIH3T3 cells. Ultimately, two reproducibly transforming cDNAs were recovered intact. One, an EWS/FLINotI cDNA, was retrovirally derived and the result of incomplete digestion. This result validates our assay by demonstrating that a cDNA with transforming potential can be carried through such a multi-step procedure. The other transforming cDNA was found to be identical to the recently described PDGF-C (Li et al., 2000) . All functional units of PDGF-C were present including N-terminal leader sequence, central CUB domain (Kristiansen et al., 1999) , and C-terminal cystine-knot region homologous to the platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) growth factor family. Taken together, these structural features strongly suggest that the PDGF-C is a secreted growth factor with the ability to transform NIH3T3 cells.
PDGF-C expression is specifically induced by biologically significant EWS fusion proteins
Isolates acting downstream of the EWS/FLI oncogenic transcription factor would be expected to have increased expression in EWS/FLI transformed cells. However, it is possible that constitutively expressed genes unaected by EWS/FLI might transform in this assay solely due to high expression levels conferred by the retroviral system. Figure 1 demonstrates that PDGF-C transcript levels are markedly upregulated in EWS/FLI transformed NIH3T3 cells.
This demonstrates that, directly or indirectly, PDGF-C is upregulated as a consequence of EWS/FLI expression and that phenotypic expression cloning can be used to isolate dierentially expressed genes.
PDGF-C is specifically induced by EWS/FLI and other related fusion genes
The variant EWS/ETS chimeras all produce clinically indistinguishable disease and similar in vitro eects . One would therefore expect a valid target of EWS/FLI also to be upregulated by these other EWS/ETS chimeras (Im et al., 2000) . We found that PDGF-C was also induced by EWS/ETS variant chimeras ( Figure 2a) including: (i) EWS/ERG, found in 5% of ES/PNET's (Sorensen et al., 1994) ; (ii) EWS/ETV, a less common variant (Jeon et al., 1995) ; and (iii) TLS/FLI, a transforming arti®cial chimera that substitutes EWS with its homologue TLS/FUS . Additionally, two attenuated mutants of EWS/FLI, del 2 (D12 ± 82) and del 9 (D82 ± 246) , were also found to upregulate PDGF-C.
Each of these EWS/ETS chimeras is associated with either EFT's or possesses substantial in vitro transforming activity. The ®nding that each chimera similarly upregulates PDGF-C suggests a link between PDGF-C and EWS/FLI transformation and tumorigenesis.
Because of the invariant structural features of EWS/ ETS chimeras (Zucman et al., 1993) and their distinctive transactivation potential (May et al., 1993b) , it is presumed that biologically relevant targets of EWS/FLI will depend on transcriptional activation by EWS/FLI and not some non-transcriptional mechanism. Figure 2b demonstrates that PDGF-C is not upregulated by EWS/FLI constructs which abrogate its essential DNA binding (Dets) and transactivation (D22) properties (May et al., 1993a) . This suggests that PDGF-C upregulation depends on EWS/FLI transcriptional activation, though that dependence may be direct or indirect.
Targets which are uniquely upregulated by EWS/FLI are more likely to be intimately involved in EFT development than targets upregulated in cells transformed by unrelated means. NIH3T3 cells are also transformed by oncogenes unrelated to EWS/FLI, including c-myc and n-ras . Even though these agents produce phenotypes similar to EWS/FLI, they do not induce PDGF-C as does EWS/ FLI (Figure 2c ). This further suggests that PDGF-C is unique to EWS/FLI transformation and is not simply a non-speci®c consequences of altered growth properties.
PDGF-C is a more potent in vitro and in vivo transforming agent than EWS/FLI
Other candidate EWS/FLI downstream eectors have shown attenuated phenotypes when compared to EWS/ FLI. This outcome suggests a contributory but secondary role in mediating EWS/FLI phenotype . To assess the relative contribution PDGF-C makes to the EWS/FLI phenotype, we compared the phenotypes induced by PDGF-C and EWS/FLI under identical circumstances. Both were expressed in untransformed NIH3T3 cells at comparably high levels (data not shown) and phenotypes were measured by soft agar colony formation and by tumor formation in SCID mice. As shown in Figure 3 , PDGF-C is more ecient than EWS/FLI at both inducing anchorage independent growth and at inducing tumor formation in immunode®cient mice.
These data indicate that PDGF-C has potent biologic activity and the eciency of its induction may be a rate-determining factor in EWS/FLI transformation. Furthermore they show how the supraphysiologic expression levels seen in retroviral expression cloning can facilitate the phenotypic isolation of downstream eectors.
PDGF-C is expressed in a high percentage of ES/PNET cell lines and primary tumors
While PDGF-C appears to be a potent mediator of EWS/FLI phenotype in a model cell line, this does not indicate a role in EWS/FLI associated human tumors. We therefore evaluated several EFT cell lines for PDGF-C expression (Figure 4a ). We found PDGF-C transcript in all lines evaluated and not in a neuroblastoma cell line (KCNR). Since cell line expression patterns can vary with passage, we also assessed expression in primary EFT specimens. As Figure 4b demonstrates, PDGF-C transcript could be demonstrated in over 60% of the primary tumors assessed. These data are consistent with a role for this biologically potent protein in a substantial number of EFT's. Further correlation with tumor clinical characteristics and with the type of EWS/ETS chimera are indicated.
PDGF-C expression is dependent on EWS/FLI
Expression of PDGF-C in tumor derived tissue suggests but does not establish it as acting downstream of EWS/FLI in EFT cells. To address this issue, we employed an EWS/FLI dominant negative construct. EWS/FLI constructs which delete the amino terminal EWS transactivation domain have been shown to inhibit EFT cell line tumorigenesis (Kovar et al., 1996) and EWS/FLI in vitro transformation through dominant negative inhibition. We introduced a construct of similar activity (data not shown) into two EFT cell lines. We used an IRES containing retroviral vector and continuous selection to ensure continued expression of the inhibitory construct. Pure polyclonal cell populations were selected and were assessed for PDGF-C expression. Figure 5 shows that dominant negative EWS/FLI resulted in lower levels of PDGF-C transcript.
These data demonstrate that, while PDGF-C expression may not be a universal feature of EFT's, its expression depends of the activity of the EWS/FLI transcription factor in tumor derived cells. It therefore represents a biologically relevant gene acting downstream of EWS/FLI. Discussion PDGF-C is a biologically potent secreted growth factor that is speci®cally induced by EWS/FLI in vitro. Its expression can be demonstrated in a majority of EFT cell lines and primary tumors. Expression in EFT cell lines appears to be EWS/FLI dependent. These data support PDGF-C as a potent mediator of the EWS/ FLI oncogenic phenotype in both in vitro systems and in human tumors.
PDGF-C has been demonstrated to be a secreted growth factor with homology to PDGF and other members of the PDGF/VEGF family (Li et al., 2000) . A wealth of evidence has implicated members of this family in the pathogenesis of a variety of tumor systems (Heldin and Westermark, 1991) . This is the ®rst report to link PDGF-C with a malignancy.
We presume PDGF-C induces transformation by closing an autocrine loop within the cell, a mechanism that is utilized by other oncogenic members of this family (Keating and Williams, 1988; Leveen et al., 1994) . PDGF-C may also act in vivo to enhance interactions between the tumor and surrounding stromal cells analogous to its predicted role in kidney development (Ding et al., 2000; Li et al., 2000) .
The ability of PDGF-C to eciently transform NIH3T3 cells is quite surprising given the recent Figure 3 PDGF-C is a more potent transforming agent than EWS/FLI. Polyclonal NIH3T3 cellular populations stably expressing either PDGF-C, EWS/FLI or vector alone (neo) were developed and assayed for transformation both (a) in vitro and (b) in vivo. (a) Speci®c quantities of cells expressing each construct were plated in soft agar as described in Materials and methods. The EWS/FLI and neo plates shown are at a 10-fold greater cell density than that of the PDGF-C plate. As can be seen, PDGF-C expression induces a much greater degree of anchorage-independent growth than does EWS/FLI or vector alone. This experiment was performed three times, and a typical result is shown. (b) 1610 6 cells expressing each construct were injected into nude mice. After 2 weeks, the average resulting tumor mass was markedly higher in mice injected with PDGF-C expressing cells (2.81 grams) than in those injected with cells expressing EWS/FLI (0.07 grams). Cells expressing vector alone resulted in no detectable tumor formation at this time point (data not shown) demonstration of its binding to the a but not the b form of the PDGF receptor (PDGFR) (Li et al., 2000) . Several studies have shown that PDGF-A, which is also thought to signal exclusively through the aPDGFR, acts only weakly to transform NIH3T3 cells (Beckmann et al., 1988; Heldin et al., 1992) . Several possibilities exist to explain these disparate outcomes of signaling through the same receptor. The dynamics of the PDGF-C/aPDGFR and PDGF-A/ aPDGFR interactions may dier such that the former leads to increased or sustained levels of activated receptors. Alternatively, PDGF-C may signal through other receptors in addition to the aPDGFR.
As with the other PDGF/VEGF family members, PDGF-C seems to also play an important role in development. PDGF-C expression is dynamically regulated during development (Ding et al., 2000) and it appears to play a role in the developing kidney, lung and other organs including the neural crest (Ding et al., 2000; Li et al., 2000) . At least in the kidney, it appears that PDGF-C is able to direct mesenchymal proliferation when secreted by adjacent epithelium. This is of interest since EFT's may arise from neural crest or primitive mesenchymal cells (de Alava and Gerald, 2000) , although no de®nitive cell of origin has yet been de®ned.
The presence of a CUB domain is unique to PDGF-C among the PDGF/VEGF family. The CUB domain has been recently shown to have an inhibitory function which is abrogated by extracellular proteolytic cleavage (Li et al., 2000) . The CUB domain may also mediate protein ± protein interactions or interactions between PDGF-C and elements of the extracellular matrix as similar domains have been shown to do in a number of developmentally regulated proteins (Li et al., 2000) . It remains to be determined if the cleaved CUB domain has biologic activity or if it serves to recruit or interact with a secondary receptor in some contexts. Further experimental and clinical evidence will be required to more ®rmly establish the importance of PDGF-C to human tumorigenesis.
Further understanding of the biology of EFT's depends on the identi®cation of biologically relevant targets of aberrant EWS/ETS chimeric transcription factors. The same can be said of a wide variety of tumor systems which harbor aberrant oncogenic transcription factors. However, instances linking oncogenic transcriptional deregulation with biologically signi®cant eectors have been relatively few (He et al., 1998; Tetsu and McCormick, 1999) . Approaches such as dierential display, RDA/SSH, SAGE, or microarrays have been widely employed to identify potential targets of oncogenic deregulation. The introduction of DNA-chip based screens further facilitates such approaches and makes them more comprehensive. However, the tumor to tumor variation thus far encountered (Perou et al., 2000) suggests that substantially more data must be analysed for func- Figure 4 PDGF-C is expressed in several EFT cell lines and primary tumor specimens. (a) A Northern blot containing total RNA from a variety of EFT-derived cancer cell lines was probed with human PDGF-C. PDGF-C transcripts were detected in all cell lines regardless of whether they contained an EWS/FLI (TC32, TC-71, TTC-475 and TTC-772) or an EWS/ERG (TTC-466) fusion. PDGF-C expression was absent in the KCNR cell line derived from an unrelated tumor type (neuroblastoma) that lacks an EWS-containing fusion. (b) PDGF-C is expressed in a large proportion of EFT primary tumors. Nested RT ± PCR with primers speci®c to a 400 bp N-terminal region of human PDGF-C was performed on 13 EFT primary tumor specimens, designated by tumor bank accession numbers, and the PNET cell line TC32. The expected fragment was detected in roughly 60% of the tumor specimens analysed. RT ± PCR on b-actin was used as a control for RNA integrity. l designates lambda HindIII marker. The marker b-actin was used for pBR327 HinfI. B designates a buer blank lane Figure 5 PDGF-C expression in EFT cell lines is dependent on EWS/FLI activity. A Northern blot containing total RNA from polyclonal, continuously selected populations of TC71 and TTC466 cells stably expressing either D22, a dominant negative EWS/FLI, or vector alone was probed with human PDGF-C. In both cell lines, blocking EWS/FLI activity with D22 decreases PDGF-C transcript levels. TC71 expresses EWS/FLI and TTC466 expresses EWS/ERG. Abundant levels of D22 transcript were detected (data not shown) tional patterns to emerge. In EFT's, the most compelling target yet identi®ed was found through a candidate gene approach based upon knowledge of promotor binding sites (Hahm et al., 1999) and not by a broader systematic screen. We have taken a contrasting approach that employs biologic selection to broadly screen and identify targets of phenotypic signi®cance. Genes identi®ed with this approach are no more likely to be direct targets than those identi®ed by any of these alternate methods. However, the biologic activity assured by our approach provides higher likelihood of target involvement in processes driving tumor development.
These data demonstrate that a primary oncogenic protein such as EWS/FLI can be eectively used to identify other oncogenic proteins that are activated downstream. Drawbacks to this approach have included the phenotypic leakiness seen in mammalian systems . In fact, we found a high incidence of false positives in our experiment. Any future strategies must account for this phenotypic variability with adequate provision for secondary screening. Recently described vector systems address this issue and have already shown promising results (Hudson et al., 1999; Maestro et al., 1999) . In the face of the complexity of oncogenic transcriptional deregulation, approaches such as ours can be a valuable complement to expression pro®ling in unraveling the complex biologic processes involved in tumor development.
Materials and methods
Expression cloning
An EWS/FLI fusion containing a NotI site within its breakpoint region was initially constructed by PCR. Oligonucleotide primers (sequence available on request) were used to amplify the EWS and Fli-1 domains respectively and to link each to an in frame NotI site. PCR products were cut with NotI and¯anking restriction endonucleases and ligated into a cloning vector. The insert was subcloned into the retroviral expression vector (SRaMSVtkneo-DHindIII) and replication-de®cient retroviral stocks were created from this construct using 293T cells and methods previously described (Muller et al., 1991) . These viral stocks were then used to transduce early passage NIH3T3 cells. After a suitable expansion and G418 selection, poly(A) + RNA was collected from each cellular population and oligo-dT primed cDNA libraries were created according to the manufacturers' protocols (Gibco ± BRL Superscript II Kit). Adapted cDNA from each population was digested with NotI and then cloned into pCTV1B, a retroviral vector designed speci®cally for expression cloning provided by Dr Robert Kay. The subsequent library ampli®cation and retroviral production steps were performed as previously described (Foster et al., 1999; Whitehead et al., 1995) . Retroviral pools representing 3610 6 bacterial clones from each library were used to transduce 3610 6 early passage NIH3T3 cells. Two days after transduction, the cells were plated in soft agar 30 plates/ library, 1.5610 5 cells/plate in 10 cm 2 plates. After 2 weeks, colonies were recovered and expanded. Secondary screening procedures via PCR ampli®cation, subcloning cDNA inserts and replating in soft agar were performed as previously described (Whitehead et al., 1995) .
Soft agar transformation assay
SRaMSVtkneoDHindIII containing full length PDGF-C, EWS/FLI or lacking insert were used to create retrovirus stocks as previously described (May et al., 1993a) . These viruses were then used to transduce equivalent populations of early passage NIH3T3 cells. After transduction, the cells were selected in G418 for at least 1 week. Polyclonal, selected populations were plated in soft agar at either 5000 or 50 000 cells per 6 cm-diameter plate and at either 10 or 20% half calf serum/half fetal calf serum in Iscove's medium as previously described. Agar plates were photographed approximately 2 weeks after plating.
Tumorigenesis assay
The same cellular populations used in the aforementioned soft agar assay were also injected subcutaneously into nude mice. Seven mice per population were injected at a single site with 1610 6 cells in 0.5 cc DMEM/5% calf serum. The mice were inspected for 2 weeks. At this time point, the mice were euthanized and the resultant tumors excised and weighed. PDGF-C and EWS/FLI transcript was demonstrated in Northern blots made from tumor samples.
Screening of cDNA library for human PDGF-C Human PDGF-C was obtained from a human TC32 library using Image Clone 307186 (Research Genetics) as a probe. Methods for library construction and screening are as previously described (Thompson et al., 1996) .
RT ± PCR of tumor samples
Five micrograms of total RNA from each tumor specimen was used to create a random hexamer-primed cDNA following the Superscript RT II protocol (Gibco). Ten per cent of the cDNA synthesis reactions from each specimen were than ampli®ed by two-stage nested PCR using PDGF-C-speci®c primers (1st stage: 5'-cggtcttggtatggagattagt, 3'-cttctaagtccaactgccatct; 2nd stage: 5'-tggatacaacttacgtttgatgaa, 3'-cgaataaggtcttccaaggtact). Cycling parameters for the ®rst stage-1 cycle6948 for 5 min; 30 cycles 6948 for 40 s, 588 for 40 s and 728 for 1 min; 728 for 7 min. Four per cent of the ®rst stage reactions was used as the template in a second PCR using the same parameters but with the second set of nested primers. Single-stage PCR was also performed in parallel on the cDNA populations with b-actin-speci®c primers (5'-tcacccacactgtgcccatctacga, 3'-cagcggaaccgctcattgccaatgg) to control for RNA integrity. Cycling parameters were identical to the ®rst stage of the aforementioned PCR.
Dominant negative EWS/FLI
A dominant negative EWS/FLI construct tagged with an amino terminal FLAG epitope was made using methods similar to those previously published . It was cloned into the retroviral expression vector pLXIN (Clontech) and used to generate amphotrophic retroviral stock using the PT67 packaging line (Clontech). To con®rm biologic activity of our construct, NIH3T3 cells expressing the dominant negative were used to superinfect either NIH3T3 cells or the same cells transduced and polyclonally selected with EWS/FLI (hygromycin resistant). These cells were then selected in G418 to obtain comparable polyclonal populations. When comparison was made to the starting population of EWS/FLI-hygromycin cells passaged in parallel, those superinfected with the dominant negative yielded smaller colonies.
Tumor cell lines were infected with the same retrovirus and selected continuously under G418 to maintain expression of the dominant negative in pure polyclonal cell populations. Expression of PDGF-C and of the dominant negative construct was con®rmed by Northern blot.
Northern blots
Total RNA was obtained using either acid phenol extraction (Trizol, Gibco ± BRL) or by column puri®cation (Qiagen Rneasy). Electrophoresis, transfer and hybridization are as previously described.
